Neonatal Subgaleal Haemorrhage – Surveillance and Management

Department Responsible for Guideline	NICU
Document Facilitator Name	Fraser Maxwell / Ben McConchie
Document Facilitator Title	Paediatrician / NICU Fellow
Document Owner Name	Jutta van den Boom
Document Owner Title	Clinical Director
Target Audience	Neonatologists; Midland Region Paediatricians and Registrars; NICU Registrars, Nurse Practitioners, Clinical Nurse Specialists and Nurses; Paediatric SHOs; LMCs; Delivery and Postnatal medical and nursing staff
Disclaimer: This document has been developed by own use. Use of this document and any reliance on is at their own risk and Waikato District Health Board	the information contained therein by any third party

Guideline Responsibilities and Authorisation

Guideline Review History

Version	Updated by	Date Updated	Summary of Changes
1	Ben McConchie/Jutta van den Boom	November 2021	New guideline

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	r Title:	itle: Paediatrician / NICU Fellow			Department:	NICU	
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY I					FOR THE DAY OF	F PRINTING	Page 1 of 9



Contents

1	Ove	rview	. 3
	1.1	Purpose	. 3
	1.2	Scope	. 3
	1.3	Patient / client group	. 3
	1.4	Procedure	. 3
	1.5	Definitions	. 3
2	Clin	ical Management	. 4
	2.1	Surveillance	.4
	2.2	Diagnosis	.4
	2.3	Management	.4
	2.4	Potential complications	. 4
3	Aud	it	. 5
	3.1	Indicators	. 5
4	Evic	lence base	. 5
	4.1	References	. 5
	4.2	Associated Waikato DHB Documents	. 5
App	endix	A: Algorithm for the Detection and Management of Neonatal SGH	. 6
App	endix	B: Management of Confirmed SGH	. 7
App	endix	C: Waikato DHB Paediatric Massive Transfusion Protocol	. 9

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	Facilitator Title: Paediatrician / NICU Fellow			Department:	NICU		
IF THIS D	IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY I					F PRINTING	Page 2 of 9

1 Overview

1.1 Purpose

- To outline surveillance for subgaleal haemorrhage after an instrumental delivery
- To describe the management of neonates with confirmed subgaleal haemorrhage.

The New Zealand Newborn Clinical Network Practice Recommendation <u>Neonatal</u> <u>Subgaleal Haemorrhage Practice Recommendation</u> (or revised versions of the recommendation) is to be considered as the Waikato District Health Board guideline for clinical management, with local practice emphasis highlighted in section 2.1 below.

1.2 Scope

All health professionals working in the Neonatal Intensive Care Unit (NICU), Delivery Suite, and Post-natal ward, also Paediatric SHO attending deliveries and post-natal ward at Waikato DHB, and in the Midland Region.

1.3 Patient / client group

Neonates delivered after successful or attempted instrumental delivery are at highest risk of developing a clinically significant subgaleal haemorrhage, particularly after vacuum assisted delivery. However, up to 1 in 2000 neonates delivered by normal vaginal delivery without instrumental assistance may develop a subgaleal haemorrhage.

1.4 Procedure

See Starship Children's Hospital Clinical Guideline <u>Neonatal Subgaleal Haemorrhage –</u> <u>Practice Recommendation</u>

Please read Starship disclaimer before proceeding further.

1.5 Definitions

Confirmed SGH	A clinically confirmed diagnosis by an NNP or Paediatric RMO or SMO in cases where SGH has been suspected.
NICU	Newborn Intensive Care Unit
NOC / NEWS	Newborn Observation Chart / Newborn Early Warning Score
Subgaleal haemorrhage (SGH)	Bleeding between the galea aponeurotica and the periosteum. It is a large potential space which may hold the entire baby's blood volume

Doc ID: 6334	Version: 01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitator Title:	Facilitator Title: Paediatrician / NICU Fellow			NICU	
IF THIS DOCUMEN	NT IS PRINTED, IT IS '	FOR THE DAY OF	F PRINTING	Page 3 of 9	

2 Clinical Management

2.1 Surveillance

Early recognition of SGH is critical for improving survival and decreasing morbidity. Ventouse assisted birth is recognised as the most important risk factor for SGH, but SGH can develop following any type of birth (e.g. vaginal, forceps or Caesarean section).

Criteria for *"Low Risk Surveillance"* and *"Intermediate Risk Surveillance"* are listed in <u>Appendix A</u>, along with the recommendations for surveillance.

Any newborn under surveillance for a subgaleal haemorrhage who meets criteria for *"High Risk Surveillance"* or is diagnosed with a Confirmed SGH (see 2.2 below) must have **immediate admission to NICU** testing as described in <u>Appendix A.</u>

The recommendations for surveillance described in The New Zealand Newborn Clinical Network Practice Recommendation <u>Neonatal Subgaleal Haemorrhage Practice</u> <u>Recommendation</u> have been adapted for use at Waikato Hospital within the NOC / NEWS.

NOC / NEWS should always be used preferentially where available. Alternatively, recording sheet is available from the <u>Neonatal Subgaleal Haemorrahge Practice</u> <u>Recommendation</u> for the documentation of surveillance observations.

2.2 Diagnosis

SGH is a clinical diagnosis, and diagnosis should NOT be delayed by imaging. Findings include a large, diffuse, fluctuating mass that crosses suture lines and develops in the first hour to hours after birth.

Further clinical manifestations are described in the <u>Neonatal Subgaleal Haemorrhage</u> <u>Practice Recommendation</u>.

The diagnosis of Confirmed SGH is made by an NNP, or Neonatal RMO or SMO and necessitates **imme diate admission to NICU**, and the management plan outlined in <u>Appendix B</u>.

2.3 Management

A newborn with Confirmed SGH must have **imme diate admission to NICU** and begin the management plan outlined in <u>Appendix B: Management of confirmed SGH</u>

Large volumes of blood products are sometimes required (as per <u>Appendix C: Waikato</u> <u>DHB Paediatric Massive Transfusion Protocol</u>),

2.4 Potential complications

A SGH can lead to serious hypovolaemia with associated diffuse intravascular coagulopathy, which is a potentially life-threatening condition.

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	r Title:	Paediatric	ian / NICU	Fellow	Department:	NICU	
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY I					FOR THE DAY OF	F PRINTING	Page 4 of 9



3 Audit

3.1 Indicators

- Full documentation of NOC/NEWS for babies at low and intermediate risk of subgaleal haemorrhage
- Management of Confirmed SGH in accordance with Appendix B

4 Evidence base

4.1 References


- New Zealand Newborn Clinical Network: Neonatal Subgaleal Haemorrhage Practice Recommendation <u>https://media.starship.org.nz/practice-recommendation-for-neonatal-subgalealhaemorrhage/Neonatal_Subgaleal_Haemorrhage_Oct_2018.pdf</u>
- Legge N, Guaran R. Critical bleeding protocol for infants used for a catastrophic subgaleal haemorrhage. J Paediatr Child Health. 2021 May 27. doi: 10.1111/jpc.15591.

4.2 Associated Waikato DHB Documents

- Instrumental Vaginal Birth guideline (Ref. 6168)
- <u>Neonatal Encephalopathy Management</u> guideline (Ref. 1588)
- Admission to Level 3 Intensive Care Nursery procedure (Ref. 4571)
- Massive Transfusion Plan protocol (Ref. 3048)
- Newborn Observation Chart and Newborn Early Warning Score guideline (Ref. 6408)

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	Facilitator Title: Paediatrician / NICU Fellow			Department:	NICU		
IF THIS D	IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY I					PRINTING	Page 5 of 9

Appendix A: Algorithm for the Detection and Management of Neonatal SGH



Observations as per NOC NEWS include HR, colour, perfusion, activity and examination of scalp, all in a good light. Pulse oximetry is recommended (intermittently) unless High Risk Surveillance when it will be continuous

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitator Title: Paediatrician / NICU Fellow				Fellow	Department:	NICU	
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY F					FOR THE DAY OF	PRINTING	Page 6 of 9

Appendix B: Management of Confirmed SGH

Send for Help

- Admit to NICU
- Consider early activation of Massive Transfusion Protocol (see <u>Appendix C</u>), see indications under 'Circulation' below
- Consider discussion with Haematologist

Airway and Breathing

- Continuously monitor RR and pulse oximetry
- Consider respiratory support or intubation and ventilation early

Circulation

- Insertion of IV access (UVC/UAC or 2 peripheral IV lines)
- Urgent capillary/venous CBC, crossmatch, coagulation profile (PR, APTT, fibrinogen) and capillary gas
- Monitor HR continuously
- Monitor BP q15min for 4 hours, then hourly for at least 4 hours once stabilised
- Monitor urine output (aim for > 1 mL/kg/hour)
- Volume expansion with 10-20mL/kg of 0.9% saline if:
 - Tachycardia > 160/min or > 20/min above baseline
 - Poor peripheral perfusion or capillary refill > 3 sec
 - Mean BP < 40 mmHg in term infant
 - pH < 7.3 or lactate > 3 mmol/L
- Inotropic support may be necessary, but mainstay of treatment is volume expansion

Blood Products and Homeostasis

- Confirm Vitamin K has been given or administer Vitamin K 1mg (= 0.1mL) IV at a rate of 1mg/minute. A dose of 1mg Vitamin K IM is also recommended at some stage.
- Coagulation profiles should be done but urgency of treatment often precludes waiting for results
- RBC transfusion if Hb < 140 g/L or at any Hb if severe hypovolaemia with RBC, O neg or type specific, 15ml/kg Can be given over 10 minutes for severe hypovolaemia or faster for extreme hypovolaemia
- If ongoing hypovolaemia, bleeding or instability due to SGH then activate 'Paediatric Massive Transfusion Protocol' (see <u>Appendix C</u>)
- Repeat CBC and coagulation studies every 4 hours until stable

Doc ID:	6334	Version: 01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	r Title:	Paediatrician / NIC	J Fellow	Department:	NICU	
IF THIS D	OCUMEN	NT IS PRINTED, IT IS	FOR THE DAY OF	PRINTING	Page 7 of 9	

 Aim for INR < 1.5, APTT < 40 sec, fibrinogen > 1g/L and platelets > 75 x 10⁹/L; however, transfusion of blood products should be driven by clinical picture. Therefore, once clinical stability has been achieved further transfusion can be stopped even if coagulation profile hasn't normalised yet.

Acidosis Treatment

Aim for pH > 7.3, lactate < 3 mmol/L

- Consider correction with Sodium Bicarbonate 8.4% if pH < 7.3 as coagulation disorders may deteriorate further at low pH
 - Half correction (mL) = Base Excess x weight (kg) x 0.3
 (i.e. BE -10 x 3kg x 0.3 = 9 mL of Sodium Bicarbonate 8.4% diluted with 9mL of sterile H20 given over 30 minutes via IV)
- Check blood gas and re-assess if further dose is indicated

Electrolytes and Glucose

- Aim for normal ionized Calcium levels (1.1 1.35 mmol/L) as ionized Calcium < 0.6 mmol/L leads to serious coagulation disorders
- · Check potassium levels as both hypo- and hyperkalaemia can occur
- Check glucose and treat appropriately

Temperature


 Aim for normothermia as each 1 °C drop in temperature leads to a 10% decrease in coagulation factor activity

Other

- Head bandaging is NOT recommended as it may increase intracranial pressure
- Imaging should await stabilisation of the infant and NOT be used to diagnose SGH
- Imaging by USS, skull X-ray, CT or MRI can be helpful to diagnose complications and co-morbidities such as hypoxic-lschemic Encephalopathy (HIE), dural tears, sagittal sinus rupture or skull fracture
- Check SBR and treat early with phototherapy as sick babies are at increased risk of kernicterus
- Keep parents informed and obtain consent for blood products transfusion

Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitato	Facilitator Title: Paediatrician / NICU Fellow			Department:	NICU		
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY					FOR THE DAY OF	PRINTING	Page 8 of 9

Appendix C: Waikato DHB Paediatric Massive Transfusion Protocol



Doc ID:	6334	Version:	01	Issue Date:	4 MAR 2022	Review Date:	4 MAR 2025
Facilitator Title:		Paediatrician / NICU Fellow			Department:	NICU	
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY FOR THE DAY OF PRINTING Page 9 of 9							